£2.8M
The seed round was led by MMC Ventures with participation from Episode 1 Ventures and Seedcamp to fund team expansion and product development.
Sable Bio
Sable Bio builds an artificial intelligence platform for pharmaceutical drug safety assessment.
£4.3MTotal raised
Sable Bio develops an artificial intelligence platform designed to help pharmaceutical companies identify safety risks early in the drug discovery process. The London-based startup provides predictive insights to reduce the risk of clinical trial failures.
Categories
Founders
JA
Josh Almond-Thynne
co-founder and CEO
Investors
- £2.8M
- £1.5M
Funding history
£1.5M
The pre seed round was led by Episode 1 Ventures and will support infrastructure development and team expansion.